Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects

This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.

Inclusion Criteria:

• Male and female subjects of non-childbearing potential between the ages of 21 and 70.
• Subjects with a BMI of 30 to 45.4 kg/m2 and total body weight >110 lbs.

Exclusion Criteria:

• Recent (6 months) unstable concurrent disease.
• History of allergic disease or drug allergies.
• Any condition affecting food consumption or absorption.